Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7



p27
actin
p27／actin
DAPI
D1NLS
+CDK4
D1NLS
+CDK4
+Skp2
D1NLS
+CDK4
+Skp2
+LC

Fig. 8



Relative cell number (folds)
1
2
3
4
5
6
0 1 2 3 4 5 6 7
Culture days
Cont
D1NLS+CDK4
D1NLS+CDK4
+Skp2
Skp2

Fig. 9



Fig. 10



Relative cell number (folds)
5
4
3
2
1
0
1
2
3
4
5
6
7
Culture days
D1NLS+CDK4+ p27siRNA
D1NLS+CDK4
p27 siRNA
Cont

Fig. 11



Lung weight (Body weight ratio)
0
1
2
3
4
5
6
7
※
#
Sham
Cont
D1NLS
Skp2

Fig. 12




40
30
20
10
0
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Sham
Cont
D1NLS
Skp2
†
#
※
※
※

Fig. 13


#
40
30
20
10
0
Infarct area (%)
Cont
D1NLS
Skp2

SEQUENCE LISTING

<110> Asubio Pharma Co., Ltd.

<120> Method for proliferating cardiomyocytes

<130> SP7689A

<150> JP P2003-391708
<151> 2003-11-21

<150> JP P2004-246533
<151> 2004-08-26

<160> 15

<170> PatentIn version 3.1

<210> 1
<211> 8
<212> PRT
<213> Simian virus 40

<400> 1

Pro Pro Lys Lys Lys Arg Lys Val
1 5

<210> 2
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> 5' primer of C-terminal cyclin D1

<400> 2
accctccatg gtagctgctg gga 23

<210> 3
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> 3' primer of C-terminal cyclin D1

<400> 3
tgatctcgag gtcgatgtcc acatctcgca cgt 33

<210> 4
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Flag tag sequence

<400> 4

Asp Tyr Lys Asp Asp Asp Asp Lys
1 5

<210> 5
<211> 66
<212> DNA
<213> Artificial Sequence

<220>
<223> 5' primer of Skp2 cDNA

<400> 5
atactcgagg ccaccatgga ctacaaggac gacgatgaca agcataggaa gcaccttcag 60

gagatt 66

<210> 6
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> 3' primer of Skp2 cDNA

<400> 6
atactcgagt catagacaac tgggcttttg cag 33

<210> 7
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Rat p27/Kip1 siRNA target sequence 1

<400> 7
ggcagaagat tcttcttc 18

<210> 8
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Rat p27/Kip1 siRNA target sequence 2

<400> 8
agcgcaagtg gaatttcga 19

<210> 9
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Rat p27/Kip1 siRNA target sequence 3

<400> 9
gtgagagtgt ctaacggga 19

<210> 10
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligo 1 for p27 siRNA-#1 expression

<400> 10
caccggtagg aggttcttct tcaacgtgtg ctgtccgttg aagaagaatc ttctgccttt 60

tt 62

<210> 11
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligo 2 for p27 siRNA-#1 expression

<400> 11
gcataaaaag gcagaagatt cttcttcaac ggacagcaca cgttgaagaa gaacctccta 60

cc 62

<210> 12
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligo 1 for p27 siRNA #4 expression

<400> 12
caccagtgta agtggagttt cgaacgtgtg ctgtccgttc gaaattccac ttgcgctttt 60

tt 62

<210> 13
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligo 2 for p27 siRNA #4 expression

<400> 13
gcataaaaaa gcgcaagtgg aatttcgaac ggacagcaca cgttcgaaac tccacttaca 60

ct 62

<210> 14
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligo 1 for p27 siRNA #6 expression

<400> 14
caccgtggga gtgtttaatg ggaacgtgtg ctgtccgttc ccgttagaca ctctcacttt 60

tt 62

<210> 15
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligo 2 for p27 siRNA #6 expression

<400> 15
gcataaaaag tgagagtgtc taacgggaac ggacagcaca cgttcccatt aaacactccc 60

ac 62